{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T17:19:44Z","timestamp":1765905584933,"version":"3.48.0"},"reference-count":0,"publisher":"Tunisian Society of Medical Sciences","issue":"2","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Tunis Med"],"abstract":"<jats:p>Introduction\u00a0: Il n'existe pas de donn\u00e9es claires sur l'incidence et les facteurs pr\u00e9dictifs des \u00e9v\u00e9nements thromboemboliques (TE) art\u00e9riels et veineux chez les patients atteints de COVID-19 et trait\u00e9s en ambulatoire.\u00a0\nObjectif\u00a0: Analyser les complications TE chez les patients atteints de COVID-19 et comparer l\u2019efficacit\u00e9 et la s\u00e9curit\u00e9 du Rivaroxaban aux h\u00e9parines \u00e0 bas poids mol\u00e9culaires (HBPM) dans le traitement prophylactique\nM\u00e9thodes\u00a0: Il s'agit d'une \u00e9tude observationnelle incluant des patients atteints de COVID-19 et trait\u00e9s en ambulatoires. Nous avons relev\u00e9 les facteurs pr\u00e9dictifs de complications thromboemboliques.\nR\u00e9sultats\u00a0: \u00a0Nous avons inclus 2089 patients atteints de COVID19 et g\u00e9r\u00e9s en ambulatoire durant la p\u00e9riode allant du 01 octobre 2020 au 31 d\u00e9cembre 2021. L\u2019\u00e2ge moyen de nos patients \u00e9tait de 43\u00b116 ans. L'incidence des complications TE veineuses et art\u00e9rielles \u00e9tait de 0,9%. Les facteurs pr\u00e9dictifs de complications thromboemboliques art\u00e9rio-veineuses \u00e9taient la contraception hormonale (OR=23), la forme clinique mod\u00e9r\u00e9e (OR=3,5), la chirurgie r\u00e9cente ou les fausses couches dans le mois pr\u00e9c\u00e9dant l\u2019atteinte par la COVID-19 (OR=9,2) et les signes tomodensitom\u00e9triques de COVID-19 (OR=4,9). Par contre, l\u2019activit\u00e9 physique s\u2019est av\u00e9r\u00e9e \u00eatre un facteur protecteur. Une thromboprophylaxie a \u00e9t\u00e9 prescrite chez 22,5% des cas\u00a0: l\u2019HBPM dans 18,1% des patients, du Rivaroxaban chez 3,7% des patients et l\u2019association des deux mol\u00e9cules successivement chez 0.6% des patients. Nous n\u2019avons pas constat\u00e9 de diff\u00e9rence statistique concernant les complications thromboemboliques ni h\u00e9morragiques majeures entre le groupe trait\u00e9 par Rivaroxaban et le groupe trait\u00e9 par HBPM.\nConclusions\u00a0: Notre \u00e9tude a montr\u00e9 que l'incidence des complications ...(r\u00e9sum\u00e9 tronqu\u00e9 \u00e0 250 mots)\n\u00a0<\/jats:p>","DOI":"10.62438\/tunismed.v103i2.5318","type":"journal-article","created":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T17:17:37Z","timestamp":1765905457000},"source":"Crossref","is-referenced-by-count":0,"title":["Facteurs pr\u00e9dictifs de complications thrombo-emboliques chez les patients atteints de Covid-19 et trait\u00e9s en ambulatoire : R\u00e9sultats de l'\u00e9tude Observationnelle TUNACOV"],"prefix":"10.62438","volume":"103","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1168-6450","authenticated-orcid":false,"given":"Rania","family":"Hammami","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aymen","family":"Dammak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Faiza","family":"Safi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nouha","family":"Ktata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hanen","family":"Maamri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mouna","family":"Baklouti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fadhila","family":"Issaoui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nejah","family":"Ben Halima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olfa","family":"Chakroun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jihen","family":"Jdidi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"31112","published-online":{"date-parts":[[2025,2,1]]},"container-title":["La Tunisie M\u00e9dicale"],"original-title":[],"deposited":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T17:17:38Z","timestamp":1765905458000},"score":1,"resource":{"primary":{"URL":"https:\/\/latunisiemedicale.com\/index.php\/tunismed\/article\/view\/5318"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,1]]},"references-count":0,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,2,1]]}},"URL":"https:\/\/doi.org\/10.62438\/tunismed.v103i2.5318","relation":{},"ISSN":["2724-7031","0041-4131"],"issn-type":[{"value":"2724-7031","type":"electronic"},{"value":"0041-4131","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2,1]]}}}